DOJ Urges DC Circuit Not To Freeze Cannabis Rescheduling

DOJ Defends Rescheduling Timeline

The Justice Department told the D.C. Circuit that no stay is warranted because the rescheduling process followed proper Administrative Procedure Act protocols and petitioners failed to show they'd suffer immediate injury. The brief, filed late Monday, responds to a coalition motion seeking to halt the DEA's final rule before it takes effect later this month.

DOJ attorneys argued that the petitioners—comprising state attorneys general and industry groups—haven't met the high bar for emergency relief. The government maintains that the rescheduling underwent rigorous scientific review by HHS and DEA. That process took three years.

Petitioners Claim Procedural Flaws

Opponents of the rescheduling argue the DEA rushed the final rule without adequate public comment periods and ignored state-level enforcement concerns. The coalition includes attorneys general from Nebraska, Kansas, and Idaho, alongside medical organizations that claim Schedule III classification contradicts FDA approval standards.

Their emergency motion filed last week asserted that allowing the rule to proceed would create immediate regulatory chaos. They pointed to conflicts between federal rescheduling and state medical marijuana programs that operate under Schedule I frameworks. State regulators say they're caught in the middle.

Schedule III Implications For Operators

Moving cannabis to Schedule III eliminates the 280E tax burden that's prevented state-legal operators from deducting ordinary business expenses, potentially saving the industry $2 billion annually. The change also opens pathways for interstate commerce and banking access, though operators would still face DEA registration requirements and manufacturing quotas.

The rescheduling represents the most significant federal cannabis policy shift since the Controlled Substances Act took effect in 1970, but it stops short of full legalization.

HHS Scientific Review Cited

The DOJ brief emphasizes that HHS conducted an eight-factor analysis concluding cannabis has accepted medical use and lower abuse potential than Schedule I or II substances. That recommendation, delivered to DEA in August 2023, triggered the rescheduling process under the Controlled Substances Act's statutory framework.

Petitioners are essentially challenging HHS's scientific conclusions, the government argues. Courts have historically given substantial deference to such findings under Chevron principles.

Timing And Effective Date

The DEA's final rule is scheduled to take effect on July 22, giving the D.C. Circuit roughly two weeks to rule on the stay motion. If the court denies the stay, rescheduling proceeds on schedule. If granted, the rule would be frozen pending full merits review—a process that could extend into 2027.

The Justice Department requested expedited consideration. It didn't propose an alternative timeline.

State-Federal Conflict Unresolved

Even under Schedule III, cannabis remains federally controlled, creating ongoing tension with the 38 states that have legalized medical or adult-use programs. The DOJ brief doesn't address how federal enforcement priorities will shift post-rescheduling, leaving operators uncertain about interstate transport and cross-border banking.

For background on the multi-year rescheduling process and its implications for state programs, see the CannIntel topic hub on DEA rescheduling.

What Happens Next

The D.C. Circuit could rule on the stay motion as early as this week, with oral arguments on the merits likely scheduled for fall 2026. Industry observers expect the court to deny the stay, given the government's procedural record and the high standard for emergency relief.

We'll be watching for the panel's order and any dissents that signal how the merits case might unfold. This is unsettled. Expect enforcement to vary by jurisdiction even if rescheduling proceeds.